Document Detail


Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
MedLine Citation:
PMID:  19590992     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of amyloidogenic immunoglobulin light chains.
Authors:
Ko-Ichi Tazawa; Nagaaki Katoh; Yasuhiro Shimojima; Masayuki Matsuda; Shu-Ichi Ikeda
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis     Volume:  16     ISSN:  1744-2818     ISO Abbreviation:  Amyloid     Publication Date:  2009  
Date Detail:
Created Date:  2010-06-11     Completed Date:  2010-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9433802     Medline TA:  Amyloid     Country:  England    
Other Details:
Languages:  eng     Pagination:  183-5     Citation Subset:  IM    
Affiliation:
Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amyloidosis / blood,  drug therapy*,  immunology,  pathology*
Antineoplastic Agents, Alkylating / therapeutic use
Humans
Immunoglobulin M / blood
Lymph Nodes / pathology,  radiography
Lymphatic Diseases / blood,  drug therapy*,  immunology,  pathology*
Male
Melphalan / therapeutic use
Middle Aged
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Immunoglobulin M; 148-82-3/Melphalan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Discriminating semantic from episodic relatedness in young and older adults.
Next Document:  Rituximab therapy in nephrotic syndrome due to AH amyloidosis.